Section 2: Qualitative and quantitative composition
I. General objectives of section 2 3 Section 2: Qualitative and quantitative composition Excipients listed in the Annex to the “Guideline on the excipients in the label and package leaflet of medicinal product for human use”
Download Section 2: Qualitative and quantitative composition
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
SUMMARY OF PRODUCT CHARACTERISTICS 1 …
www.sanofi-aventis.co.ukSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Targocid 200mg Teicoplanin 200mg Powder for Injection Targocid 400mg Teicoplanin 400mg Powder for Injection
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
www.baxter.inOliClinomel N4-550E: The maximum daily dose is 40ml/kg body weight (equivalent to 0.88 g of amino-acids, 3.2 g of glucose and 0.8 g of lipids per kg), i.e. 2,800 ml …
AUSTRALIAN PRODUCT INFORMATION PANADOL …
www.medicines.org.au4 PANADOL CHILDREN 1 to 5 YEARS COLOURFREE SUSPENSION AGE AVERAGE WEIGHT DOSE 1 – 2 years 10 - 12 kg 6 - 8 mL 2 – 3 years 12 - 14 kg 8 - 9 mL
AUSTRALIAN PRODUCT INFORMATION PANADOL …
www.medicines.org.au1 australian product information panadol osteo (paracetamol) tablets 1 name of the medicine paracetamol 2 qualitative and quantitative composition
2. QUALITATIVE AND QUANTITATIVE …
www.medsafe.govt.nzInternal document code 1 Cyc11 0418iNZ NEW ZEALAND DATA SHEET 1. PRODUCT NAME CYCLOGYLTM (cyclopentolate hydrochloride) Eye Drops 1.0% 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
2. QUALITATIVE AND QUANTITATIVE …
www.medsafe.govt.nzInternal document code 1 max040418iNZ . NEW ZEALAND DATA SHEET . 1. PRODUCT NAME . MaxidexTM (dexamethasone) 0.1% sterile ophthalmic suspension and ointment.. 2. QUALITATIVE AND QUANTITATIVE